Greenwich LifeSciences, Inc. Logo

Greenwich LifeSciences, Inc.

Developing an immunotherapy vaccine to prevent recurrence in HER2-positive breast cancer patients.

GLSI | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
3992 BLUEBONNET DR, BUILDING 14, 77477 STAFFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company pioneering the development of GLSI-100 (also known as GP2), an immunotherapy to prevent the recurrence of breast cancer. The company's lead candidate is a peptide-based vaccine designed to activate the immune system to target HER2-positive cancer cells. GLSI-100 is aimed at patients who have undergone surgery and completed standard-of-care treatments. Following a successful Phase IIb trial that showed a significant reduction in recurrence rates and a well-tolerated safety profile, the therapy is now advancing through a global Phase III clinical trial, Flamingo-01. The treatment has been granted Fast Track Designation by the U.S. FDA, highlighting its potential to address a critical unmet need in oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Greenwich LifeSciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Greenwich LifeSciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Greenwich LifeSciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Specializes in hormone drugs for OB/GYN, urology, internal medicine, and animal health.
Japan 4886
Aspire Biopharma Holdings, Inc. Logo
Developing a nano-platform for rapid, sublingual delivery of reformulated medications.
United States of America ASBP
ASSEMBLY BIOSCIENCES, INC. Logo
Clinical-stage biopharma developing small-molecule antivirals for herpes, HBV, and HDV.
United States of America ASMB
Assertio Holdings, Inc. Logo
Offers branded prescription drugs for neurology, pain, and CNS to US patients.
United States of America ASRT
Astellas Pharma Inc. Logo
A global pharmaceutical company developing innovative medicines for unmet needs, focusing on oncology.
Japan 4503
Astena Holdings Co., Ltd. Logo
Develops and sells chemicals, pharma, and ingredients for food, cosmetic, and industrial use.
Japan 8095
AstraZeneca PLC Logo
Global biopharma developing medicines for oncology, cardiovascular, respiratory & rare diseases.
United Kingdom AZN
ASTRAZENECA PLC Logo
Biopharmaceutical firm developing medicines for oncology, rare diseases, and metabolic disorders.
United States of America AZN
Astria Therapeutics, Inc. Logo
Developing long-acting therapies for rare allergic and immunologic diseases like HAE.
United States of America ATXS
ATAI Life Sciences N.V. Logo
Clinical-stage biopharma creating novel psychedelic drugs for mental health disorders.
United States of America ATAI

Talk to a Data Expert

Have a question? We'll get back to you promptly.